From: BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
Patient’s parameters | BCL2 expression | ||
---|---|---|---|
Low (n = 87) | High (n = 86) | P | |
Sex, male/female | 49/38 | 43/43 | 0.448 |
Median age, years (range) | 61 (22–82) | 56 (18–88) | 0.106 |
Median WBC, ×109/L (range) | 17.9 (0.6–223.8) | 15.25 (0.4–297.4) | 0.041 |
Median PB blasts, % (range) | 24 (0–94) | 46 (0–98) | 0.033 |
Median BM blasts, % (range) | 73 (30–98) | 72 (30–100) | 0.893 |
FAB classifications | Â | Â | 0.000 |
 M0 | 4 | 12 | 0.038 |
 M1 | 15 | 29 | 0.015 |
 M2 | 21 | 17 | NS |
 M3 | 5 | 11 | NS |
 M4 | 22 | 12 | NS |
 M5 | 16 | 2 | 0.001 |
 M6 | 1 | 1 | NS |
 M7 | 1 | 2 | NS |
 No data | 2 | 0 | NS |
Cytogenetics | Â | Â | 0.239 |
 Normal | 44 | 32 | NS |
 t(15;17) | 5 | 10 | NS |
 t(8;21) | 6 | 1 | NS |
 inv.(16) | 3 | 7 | NS |
  + 8 | 3 | 5 | NS |
 del(5) | 0 | 1 | NS |
 -7/del(7) | 4 | 4 | NS |
 11q23 | 2 | 1 | NS |
 Others | 10 | 9 | NS |
 Complex | 9 | 15 | NS |
 No data | 1 | 1 | NS |
Gene mutation | |||
 FLT3 (+/−) | 23/64 | 26/60 | 0.616 |
 NPM1 (+/−) | 28/59 | 20/66 | 0.235 |
 DNMT3A (+/−) | 23/64 | 19/67 | 0.595 |
 IDH2 (+/−) | 9/78 | 8/78 | 1.000 |
 IDH1 (+/−) | 5/82 | 11/75 | 0.124 |
 TET2 (+/−) | 9/78 | 6/80 | 0.590 |
 RUNX1 (+/−) | 5/82 | 10/76 | 0.188 |
 TP53 (+/−) | 6/81 | 8/78 | 0.590 |
 NRAS (+/−) | 5/82 | 7/79 | 0.566 |
 CEBPA (+/−) | 7/80 | 6/80 | 1.000 |
 WT1 (+/−) | 2/85 | 8/78 | 0.057 |
 PTPN11 (+/−) | 3/84 | 5/81 | 0.496 |
 KIT (+/−) | 5/82 | 2/84 | 0.443 |
 U2AF1 (+/−) | 4/83 | 3/83 | 1.000 |
 KRAS (+/−) | 4/83 | 3/83 | 1.000 |
 SMC1A (+/−) | 5/82 | 2/84 | 0.443 |
 SMC3 (+/−) | 4/83 | 3/83 | 1.000 |
 PHF6 (+/−) | 1/86 | 4/82 | 0.211 |
 STAG2 (+/−) | 2/85 | 3/83 | 0.682 |
 RAD21 (+/−) | 4/83 | 0/86 | 0.121 |